Payment overview · 2025
General Payments
$2,719.60
132 reported records · 31 companies
Healthcare provider profile · identity verified
Sunil Mathews, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · IRVING, TX · NPI 1255437067
Verified facts
What the public records show
CMS Open Payments records show Sunil Mathews, M.D. received $2,719.60 in general payments during 2025 across 132 reported records.
ABBVIE INC. accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Rytary by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fycompa by this doctor in 2024.
KYOWA KIRIN, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NOURIANZ as an associated drug or biological on 307 records involving 305 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nourianz by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $421.90 | 15.5% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $330.16 | 12.1% | 16 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $314.61 | 11.6% | 12 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $263.55 | 9.7% | 21 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $156.62 | 5.8% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $151.78 | 5.6% | 6 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $106.52 | 3.9% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $92.72 | 3.4% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $85.68 | 3.1% | 4 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $78.96 | 2.9% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.24 | 2.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.74 | 2.5% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $65.86 | 2.4% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $64.76 | 2.4% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $50.08 | 1.8% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$47.74 | 1.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $32.11 | 1.2% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.59 | 1.1% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $27.63 | 1.0% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $27.55 | 1.0% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $26.12 | 1.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $26.09 | 1.0% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $26.00 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.13 | 0.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.82 | 0.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.85 | 0.7% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.63 | 0.7% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.48 | 0.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.39 | 0.6% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $16.21 | 0.6% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.08 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,719.60 | 132 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $338.47 | 18 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $314.61 | 12 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $208.59 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $198.80 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $195.90 | 10 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $156.62 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $151.78 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $144.45 | 6 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $118.36 | 5 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $92.72 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $85.68 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $85.68 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $73.24 | 4 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $65.86 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $64.76 | 3 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $62.13 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $60.72 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $50.08 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.82 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $47.74 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $45.80 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $45.00 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $32.11 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $30.59 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| KYOWA KIRIN, INC. Exact reporting entity; no affiliate inference |
2025 | NOURIANZ open payments reported associated product |
CMS Open Payments — General Payments 307 supporting records · 305 recipient NPIs · example record 1222071383 |
Nourianz · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 194 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 58 |
| Gabapentin | Gabapentin | 190 | 49 |
| Trazodone Hcl | Trazodone Hcl | 143 | 30 |
| Memantine Hcl | Memantine Hcl | 139 | 39 |
| Rytary | Carbidopa/Levodopa | 87 | 20 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 72 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | 19 |
| Clonazepam | Clonazepam | 71 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 18 |
| Pregabalin | Pregabalin | 55 | 13 |
| Modafinil | Modafinil | 50 | 13 |
| Entacapone | Entacapone | 42 | suppressed |
| Levetiracetam Er | Levetiracetam | 42 | 13 |
| Neupro | Rotigotine | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 14 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Levetiracetam | Levetiracetam | 35 | 11 |
| Primidone | Primidone | 33 | suppressed |
| Lacosamide | Lacosamide | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Nourianz | Istradefylline | 22 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 20 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Fycompa | Perampanel | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nayzilam | Midazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,719.60 · 132 records | ABBVIE INC. | BOTOX, BRIUMVI, CREXONT, FIRDAPSE, GOMEKLI, Gamunex-C, General - DBS, Gocovri, HYQVIA, Hizentra, KESIMPTA, KISUNLA, Leqembi, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, Rystiggo, Sunosi, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYEPTI, VYVGART, XYWAV, ZAVZPRET, ZEPOSIA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error